Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPP2: MDMA-Assisted Therapy for PTSD
NCT04077437Phase 3Completed
- Sponsor
- Lykos Therapeutics
- Start
- Sep 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Lykos Therapeutics. Started Sep 2020; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04077437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077437.